可手术I期非小细胞肺癌碳离子放疗后五年生存结局:日本全国登记研究(J-CROS-LUNG)
日本2016至2018年纳入136例可手术I期非小细胞肺癌患者,接受碳离子放疗(CIRT),中位随访56个月;5年总生存率81.8%、病因特异性生存率91.2%、无进展生存率65.9%、局部控制率95.8%;无4级及以上毒性,1例发生3级放射性肺炎。
要点
- 5年总生存率81.8%、病因特异性生存率91.2%,局部控制率95.8%。
- 无4级及以上毒性,仅1例发生3级放射性肺炎。
- 多因素分析显示年龄与总生存显著相关(p=0.018)。
核心结论
- 作者认为,碳离子放疗对可手术I期非小细胞肺癌患者取得了良好结局,毒性可耐受。
研究设计与样本
- 日本前瞻性全国登记研究(J-CROS-LUNG),纳入2016至2018年日本全部接受碳离子放疗的可手术I期非小细胞肺癌患者136例;剂量分割方案选自日本放射肿瘤学会批准的若干选项,碳离子放疗仅照射原发肿瘤、不照射淋巴结。
主要发现
- 中位随访56个月;136例中117例(86%)为临床IA期,19例(14%)为临床IB期,50例(37%)为临床诊断未获组织学诊断,97%肿瘤位于外周。
- 5年总生存率81.8%(95%CI:75.1-89.2),病因特异性生存率91.2%(95%CI:86.0-96.8),无进展生存率65.9%(95%CI:58.2-74.6),局部控制率95.8%(95%CI:92.3-99.5)。
- 多因素分析显示年龄是总生存的显著影响因素(p=0.018),年龄(p=0.010)和实性成分/肿瘤比值(p=0.004)是无进展生存的显著影响因素。
- 无4级及以上毒性,1例患者发生3级放射性肺炎。
临床怎么用
- 作者认为碳离子放疗对可手术I期非小细胞肺癌患者取得了良好结局、毒性可耐受,原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The standard therapy for stage I NSCLC is surgery, but some operable patients refuse this option and instead undergo radiotherapy. Carbon-ion radiotherapy (CIRT) is a type of radiotherapy. The Japanese prospective nationwide registry study on CIRT began in 2016. Here, we analyzed real-world clinical outcomes of CIRT for operable patients with stage I NSCLC. METHODS: All patients with operable stage I NSCLC treated with CIRT in Japan between 2016 and 2018 were enrolled. The dose fractionations for CIRT were selected from several options approved by the Japanese Society for Radiation Oncology. CIRT was delivered to the primary tumor, not to lymph nodes. RESULTS: The median follow-up period was 56 months. Among 136 patients, 117 (86%) had clinical stage IA NSCLC and 19 (14%) had clinical stage IB NSCLC. There were 50 patients (37%) diagnosed clinically without having been diagnosed histologically. Most tumors (97%) were located in the periphery. The 5-year overall survival, cause-specific survival, progression-free survival, and local control rate were 81.8% (95% confidence interval [CI]: 75.1-89.2), 91.2% (95% CI: 86.0-96.8), 65.9% (95% CI: 58.2-74.6), and 95.8% (95% CI: 92.3-99.5), respectively. Multivariate analysis identified age as a significant factor for overall survival (p = 0.018), whereas age and consolidation/tumor ratio (p = 0.010 and p = 0.004) were significant factors for progression-free survival. There was no grade 4 or higher toxicity. Grade 3 radiation pneumonitis occurred in one patient. CONCLUSIONS: This study reports the long-term outcomes of CIRT for operable NSCLC in the real world. CIRT for operable patients has been found to have favorable outcomes, with tolerable toxicity.
引用
- Kubo N, Suefuji H, Nakajima M, et al. Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG). J Thorac Oncol. 2023. PMID: 37924974. doi:10.1016/j.jtho.2023.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。